Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPH9788 Tablet in Chinese Healthy Subjects.’ The study aims to assess the safety of SPH9788 tablets in healthy participants, which is crucial for advancing the drug to further clinical phases.
The intervention being tested is the SPH9788 tablet, an experimental drug administered orally, with the purpose of evaluating its safety and tolerability. A placebo is used as a comparator to ensure the reliability of results.
This is a Phase I interventional study with a randomized, sequential intervention model. It employs a double-blind masking approach, meaning both participants and investigators are unaware of who receives the actual drug or placebo. The primary aim is treatment-focused.
The study began on February 18, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on March 25, 2025. These dates are important for tracking the study’s progress and potential market entry.
The outcome of this study could significantly impact Shanghai Pharmaceuticals’ stock performance, as successful results may boost investor confidence and market position. Competitors in the pharmaceutical industry will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.